KEI Response to Questions from USTR on Special 301 – March 5, 2021
Government Funded research
NIST Proposed Revisions to Bayh-Dole Act Regulations
New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading
KEI RN-2021-1. US government COVID contracts definitions of practical application
KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment
On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading
KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa
On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading
Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights
KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading
Draft of EU export restriction for COVID-19 vaccines
Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products
One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading
Agenda: Jan 27, 2021 Discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes
This is the agenda for a discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes. The proposals for the changes in regulations were noticed on January 4, 2021, and the proposed changes in the statutes were published on… Continue Reading
President Ursula von der Leyen on COVID-19 (Davos Agenda Week): “And now, the companies must deliver. They must honour their obligations.”
On Tuesday, 26 January 2021, Dr. Ursula von der Leyen, President of the European Commission delivered a special address at “Davos Agenda Week” devoting much of her speech to the European Union’s response to the COVID-19 pandemic. While President von… Continue Reading